WO2012003129A3 - Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host - Google Patents

Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host Download PDF

Info

Publication number
WO2012003129A3
WO2012003129A3 PCT/US2011/041567 US2011041567W WO2012003129A3 WO 2012003129 A3 WO2012003129 A3 WO 2012003129A3 US 2011041567 W US2011041567 W US 2011041567W WO 2012003129 A3 WO2012003129 A3 WO 2012003129A3
Authority
WO
WIPO (PCT)
Prior art keywords
pvkv
ll3b
fmdv
vaccine
viruses
Prior art date
Application number
PCT/US2011/041567
Other languages
French (fr)
Other versions
WO2012003129A2 (en
Inventor
Aida E. Rieder
Luis L. Rodriguez
Jason R. Hollister
Sabena Uddowla
Original Assignee
The United States Of America, As Represented By The Secretary Of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary Of Agriculture filed Critical The United States Of America, As Represented By The Secretary Of Agriculture
Publication of WO2012003129A2 publication Critical patent/WO2012003129A2/en
Publication of WO2012003129A3 publication Critical patent/WO2012003129A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32161—Methods of inactivation or attenuation
    • C12N2770/32162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32161—Methods of inactivation or attenuation
    • C12N2770/32163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32171—Demonstrated in vivo effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)

Abstract

We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. Mutations were introduced into MAb F32-44 epitope in FMDV A24Cruzeiro spanning residues H27N31 in 3Dpol protein to obtain the homologous amino acid sequence of bovine rhinitis virus type B (BRV-2, Y27R31). Mutations in 3B consisted of a deletion of 3B1 and a mutation in 3B2 (RQKP->PVKV, found in BRV-2) that abolishes reactivity with MAb F8B. These attenuated marker viruses provide safe alternatives for FMD vaccine manufacturing. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. Chimeric viruses were produced to contain the capsid of distantly related type A/Turkey/06 or Asia type FMDV: Asia1-A24LL3BPVKV3DYR and A/Turkey/06 -A24LL3BPVKV3DYR. A24LL3DYR and A24LL3BPVKV3DYR mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR or the chimeric A-Turkey/06-A24LL3BPVKV3DYR or Asia1-A24LL3BPVKV3DYR viruses. Cattle immunized with chemically inactivated A24LL3DYR and A24LL3BPVKV3DYRvaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine and protected 100% the animals from challenge with parental virus. The single and double marked-FMDV vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
PCT/US2011/041567 2010-07-01 2011-06-23 Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host WO2012003129A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36071910P 2010-07-01 2010-07-01
US61/360,719 2010-07-01
US13/157,097 US8765141B2 (en) 2010-07-01 2011-06-09 Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
US13/157,097 2011-06-09

Publications (2)

Publication Number Publication Date
WO2012003129A2 WO2012003129A2 (en) 2012-01-05
WO2012003129A3 true WO2012003129A3 (en) 2012-07-05

Family

ID=45402637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/041567 WO2012003129A2 (en) 2010-07-01 2011-06-23 Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host

Country Status (2)

Country Link
US (2) US8765141B2 (en)
WO (1) WO2012003129A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2498814B1 (en) 2009-11-02 2015-09-09 The Trustees of the University of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
CN114045295A (en) * 2013-03-15 2022-02-15 宾夕法尼亚大学理事会 Foot and Mouth Disease Virus (FMDV) consensus proteins, coding sequences thereof, and vaccines made therefrom
EP3046580A2 (en) 2013-09-19 2016-07-27 Zoetis Services LLC Oil-based adjuvants
PT3244920T (en) 2015-01-16 2023-07-28 Zoetis Services Llc Foot-and-mouth disease vaccine
CN104792990A (en) * 2015-03-31 2015-07-22 洛阳莱普生信息科技有限公司 A-type foot-and-mouth disease competition ELISA antibody detection kit
US9975926B2 (en) * 2015-12-08 2018-05-22 The United States of America, as Represented by the Secretary of Homeland Security Methods of making and using vaccines utilizing minicircle DNA expression vectors for production of foot-and-mouth-disease virus proteins and virus-like particles
TWI760322B (en) * 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 Recombinant adenovirus vectored fmdv vaccines and uses thereof
US10435695B2 (en) 2016-09-08 2019-10-08 The Government of the United States of America, as represented by the Secretary of Homeland Security Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences
US10385319B2 (en) 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
CN106706924A (en) * 2016-12-08 2017-05-24 申联生物医药（上海）股份有限公司 Competitive ELISA qualitative and quantitative detection method of oil adjuvant vaccine
CN107201346B (en) * 2017-03-22 2020-12-22 中国农业科学院兰州兽医研究所 Foot-and-mouth disease marked vaccine strain with 3B protein dominant epitope deletion and construction method and application thereof
CN108251380A (en) * 2018-02-26 2018-07-06 新疆畜牧科学院兽医研究所 A kind of 7E8 cell strain of monoclonal antibody preparation method of resistant to foot and mouth disease 3B albumen and application
CN111273035A (en) * 2020-03-06 2020-06-12 中国农业科学院兰州兽医研究所 Chemiluminescence kit for quantitatively detecting non-structural protein residues in foot-and-mouth disease inactivated vaccine and detection method thereof
CN116249708A (en) * 2020-05-27 2023-06-09 美国农业部 Foot-and-mouth disease live attenuated strain modified through optimization and application thereof
CA3185141A1 (en) * 2020-05-27 2021-12-02 The United States Of America, As Represented By The Secretary Of Agriculture Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
CN111744000B (en) * 2020-07-14 2021-03-23 中国农业科学院兰州兽医研究所 Foot-and-mouth disease recombinant virus with reduced immunosuppressive function and preparation method and application thereof
CN111944770B (en) * 2020-08-27 2022-04-15 中国农业科学院兰州兽医研究所 Foot-and-mouth disease virus attenuated mutant strain and preparation method and application thereof
CN112029735B (en) * 2020-08-31 2022-04-12 中国农业科学院兰州兽医研究所 Foot-and-mouth disease virus non-structural protein 3B dominant epitope deletion marker strain and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824316A (en) * 1996-05-24 1998-10-20 The United States Of America As Represented By The Secretary Of Agriculture Leader-proteinase deleted foot-and-mouth disease viruses and their use as vaccines
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
US20040001864A1 (en) * 2000-06-29 2004-01-01 King Andrew Maurice Quatermain Vaccine against foot-and-mouth disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824316A (en) * 1996-05-24 1998-10-20 The United States Of America As Represented By The Secretary Of Agriculture Leader-proteinase deleted foot-and-mouth disease viruses and their use as vaccines
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
US20040001864A1 (en) * 2000-06-29 2004-01-01 King Andrew Maurice Quatermain Vaccine against foot-and-mouth disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. C. BROWN ET AL.: "Pathogenesis of Wild-Type and Leaderless Foot-and-Mouth Disease Virus in Cattle.", JOURNAL OF VIROLOGY., vol. 70, no. 8, 1996, pages 5638 - 5641 *
MARGARITA SAIZ ET AL.: "Foot-and-mouth disease virus: biology and prospects for disease control.", MICROBES AND INFECTION., vol. 4, no. ISSUE, 2002, pages 1183 - 1192 *
MING YANG ET AL.: "Identification of a major antibody binding epitope in the non-structural protein 3D of foot-and-mouth disease virus in cattle and the development of a monoclonal antibody with diagnostic applications.", JOURNAL OF IMMUNOLOGICAL METHODS., vol. 321, no. ISSUES, 2007, pages 174 - 181 *

Also Published As

Publication number Publication date
WO2012003129A2 (en) 2012-01-05
US20120315295A1 (en) 2012-12-13
US9180179B1 (en) 2015-11-10
US8765141B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
WO2012003129A3 (en) Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
Mayr et al. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs
Yang et al. Immunogenicity and protective efficacy of an inactivated cell culture-derived Seneca Valley virus vaccine in pigs
von Teichman et al. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves
AU2014310676B2 (en) Fowl Adenovirus vaccin
EP3035953B1 (en) Fowl adenovirus vaccine
Park et al. Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats
Lin et al. Novel subunit vaccine with linear array epitope protect giant grouper against nervous necrosis virus infection
Sadiq et al. Effect of rotavirus genetic diversity on vaccine impact
Munang'andu et al. Immunogenicity and cross protective ability of the central VP2 amino acids of infectious pancreatic necrosis virus in Atlantic salmon (Salmo salar L.)
US20110311568A1 (en) Vaccine
Cao et al. Evaluation of cross-protection against three topotypes of serotype O foot-and-mouth disease virus in pigs vaccinated with multi-epitope protein vaccine incorporated with poly (I: C)
Kortekaas et al. Rift Valley fever vaccine development, progress and constraints
Xu et al. Immunogenicity of T7 bacteriophage nanoparticles displaying GH loop of foot-and-mouth disease virus (FMDV)
Fowler et al. A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease
Hajam et al. Co-administration of flagellin augments immune responses to inactivated foot-and-mouth disease virus (FMDV) antigen
Novo et al. Efficacy of a high quality O1/Campos foot-and-mouth disease vaccine upon challenge with a heterologous Korean O Mya98 lineage virus in pigs
Excler et al. Toward developing a preventive MERS-CoV vaccine-report from a workshop organized by the Saudi Arabia ministry of health and the international vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015
Reeth et al. Vaccines and vaccination for swine influenza: differing situations in Europe and the USA
Hwa et al. Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine
Zhang et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71
Kim et al. Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus
Wei et al. Overview of the recent advances in porcine epidemic diarrhea vaccines
Rai et al. Novel 6xHis tagged foot-and-mouth disease virus vaccine bound to nanolipoprotein adjuvant via metal ions provides antigenic distinction and effective protective immunity
Guerra et al. Immunization with a small fragment of the Schmallenberg virus nucleoprotein highly conserved across the Orthobunyaviruses of the Simbu serogroup reduces viremia in SBV challenged IFNAR-/-mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11801337

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11801337

Country of ref document: EP

Kind code of ref document: A2